Post-myocardial infarction care and cardiac rehabilitation

• A myocardial infarction (MI) scars a part of the heart muscle; the days and weeks after it are when dangerous complications are most likely, and when the plan that decides long-term survival is set.
• Complications divide into three useful groups: mechanical (pump failure, free-wall or septal rupture, papillary-muscle failure with acute mitral regurgitation), arrhythmic (ventricular tachyarrhythmias and bradyarrhythmias), and pericardial (early infarct pericarditis and the rare late Dressler syndrome).
• Secondary prevention means doing everything that stops a second event: antiplatelet and antithrombotic drugs, a high-intensity statin with a low-density lipoprotein cholesterol (LDL-C) target, blood-pressure and diabetes control, stopping smoking, and a healthy diet.
• Cardiac rehabilitation is not optional exercise: it is a structured, multidisciplinary programme that starts in hospital and is the safest way back to normal activity.
• Driving (UK rule used here as one worked example) is paused for 4 weeks after an uncomplicated MI, and return to work depends on the job, heart function and the person, not on a fixed date.

By the end of this page you should be able to:

1. List the mechanical, arrhythmic and pericardial complications of MI and recognise which are surgical emergencies.
2. Choose secondary-prevention drug therapy after an MI and state the lipid, blood-pressure and glycaemic targets used.
3. Plan cardiac rehabilitation, including when it starts, what it must contain, and who must not be excluded.
4. Give practical advice on driving, flying, return to work and sexual activity after an MI.
5. Arrange follow-up (visits, left-ventricular reassessment, implantable defibrillator assessment) and know when to refer.
6. Explain why ESC and NICE recommendations differ slightly, and what to do in a low-resource setting.

This page is the aftercare of an MI: the in-hospital convalescence, the complications to hunt for, and the long-term prevention that turns a heart attack into a manageable chronic disease. It assumes the MI has already been diagnosed and reperfused. The acute management of chest pain, thrombolysis and primary angioplasty are covered in their own topics; heart failure and atrial fibrillation are treated separately. A first-time reader can read straight through.

An MI kills myocardial cells, leaves a scar, and sometimes thins or stretches the ventricular wall. The short-term risk is mechanical or electrical failure of the damaged heart; the long-term risk is a second, often fatal, event. Modern therapy therefore has two jobs at once: nurse the damaged heart through the first weeks, and strip the atherosclerosis and risk factors that produced it. Both start before the patient leaves hospital, because the first outpatient appointment is too late for many of the decisions that matter.

Even after a successful primary angioplasty, a heart-attack ward is doing three things: watching for complications, starting the drugs that will be taken for life, and teaching the patient. The length of stay is short for uncomplicated infarcts (high-risk patients are considered for discharge within 48 to 72 hours when early rehabilitation and follow-up are arranged) and longer when heart failure, arrhythmia or mechanical problems appear. ^[2]

Discharge is a clinical handover to two people: the general practitioner and the patient. The summary should record:

• confirmation of the diagnosis of acute MI;
• results of investigations (including left-ventricular function);
• incomplete drug titrations with dates and target doses;
• future management and follow-up plans;
• advice on secondary prevention. ^[3]

Medication reconciliation at discharge is the single most common place where prevention is lost. A drug started in hospital and never uptitrated is a missed opportunity.

Left-ventricular (LV) function must be assessed in every patient after a STEMI and in every patient after an NSTEMI. ^[3] It is the single variable that drives three later decisions: whether a beta-blocker is continued indefinitely, whether an angiotensin-converting enzyme (ACE) inhibitor is essential, and whether an implantable cardioverter-defibrillator (ICD) is needed. Echocardiography is the usual test; if it is inconclusive, cardiac magnetic resonance imaging is considered. ^[2]

Complications are classified by mechanism, so that one is not missed. Most are front-loaded: they occur in hospital, often soon after the infarct and usually within the first week. Every patient after an MI should be treated as being at risk of them until an uncomplicated course has been demonstrated.

These arise because the infarcted wall is soft, thin and under tension. They are uncommon with modern early reperfusion, but each is life-threatening and must enter the differential of a patient who deteriorates suddenly after an MI.

• Left-ventricular pump failure and cardiogenic shock. A large infarct leaves too little functioning muscle. The patient becomes breathless, oliguric, cold and hypotensive. This is managed in a cardiac intensive care unit; mechanical circulatory support and coronary revascularisation are considered case by case.
• Free-wall rupture with bleeding into the pericardium (cardiac tamponade). It classically produces sudden collapse or electromechanical dissociation in the first few days after a transmural infarct. It is a surgical emergency.
• Ventricular septal rupture, producing an abrupt left-to-right shunt. A new harsh systolic murmur and sudden haemodynamic deterioration are the clues. It needs urgent surgical (or occasionally catheter-based) repair. ^[2]
• Acute mitral regurgitation from papillary-muscle rupture or dysfunction, with severe regurgitation and pulmonary oedema. It too is a surgical emergency.
• Left-ventricular aneurysm or pseudoaneurysm, a late structural complication of a completed large infarct, presenting with heart failure, arrhythmia or thromboembolism.
• Left-ventricular thrombus and systemic embolism. Akinetic or dyskinetic myocardium, particularly at the apex after an anterior infarct, can form mural thrombus that embolises to brain, limbs or the visceral circulation. Echocardiography before discharge is used to exclude it. ^[2]

The infarcted and reperfused myocardium is electrically unstable. Ventricular tachycardia and ventricular fibrillation remain an important cause of early death; bradyarrhythmias are common in right-coronary and right-ventricular infarction because the sinus and atrioventricular nodes are affected. High-risk patients should be monitored with electrocardiography (ECG) in a cardiac care or intensive cardiac care unit for at least 24 hours, moved to a monitored bed for a further 24 to 48 hours once uncomplicated after reperfusion, and considered for discharge within 48 to 72 hours when early rehabilitation and follow-up are arranged. ^[2]

Practical points:

• Correct hypokalaemia and hypomagnesaemia.
• Treat ischaemia rather than chasing the rhythm in isolation.
• New atrial fibrillation after an MI worsens prognosis and complicates antithrombotic therapy, because the patient then has two indications for anticoagulation (stroke prevention and the coronary event).
• A sustained ventricular arrhythmia, or a reduced left-ventricular ejection fraction (LVEF) below 40% before discharge, triggers a later defibrillator assessment at 6 to 12 weeks. ^[2]
• Late (after the first year) ventricular arrhythmias are usually a marker of heart failure rather than of the infarct itself; they belong to chronic heart-failure management.

Pericarditis after an MI comes in two distinct forms, and confusing them is a common trap.

• Early post-infarction pericarditis occurs within days, usually after a large transmural infarct or a late-presenting infarct with free-wall involvement. It is rare in the reperfusion era and is usually self-limited. Treatment is supportive; if symptoms persist, aspirin plus colchicine may be used, while corticosteroids should be avoided because of concerns about myocardial healing and bleeding. ^[5]
• Late post-infarction (Dressler) syndrome appears weeks to months later and behaves like post-cardiac injury syndrome (PCIS): fever, pleuritic pain, a pericardial effusion. Management is the standard anti-inflammatory approach. ^[5] It is rare: early and late post-MI pericarditis together occur in under 5% and under 1% of cases respectively in the modern era, compared with 1 to 5% in the pre-reperfusion literature. ^[5]

Because post-MI myopericarditis sits on the same spectrum as pericarditis, any suspected MI patient with chest pain should have acute coronary syndrome excluded first. Cardiac troponin and haemodynamics remain the priority.

Pericardial effusions are common after cardiac surgery and need careful interpretation. In post-MI PCIS, an effusion greater than 10 mm is associated with a higher risk of tamponade or free-wall rupture. ^[5] Pericarditis itself is diagnosed clinically using the standard ESC criteria (at least two of: typical chest pain, pericardial friction rub, diffuse ST-segment elevation or PR depression on ECG, new pericardial effusion) plus raised inflammatory markers. ^[5]

Secondary prevention starts in hospital and continues for life. It has three layers: drugs, risk-factor targets, and behaviour. No single layer is sufficient on its own.

A survivor of an MI is discharged on a small set of drugs that act on different pathways; each has a clear stop rule and a titration plan. The evidence of benefit is strong for all four core drugs. ^[3]

Blood glucose. Hyperglycaemia on admission should be managed to keep blood glucose below 11.0 mmol/L while avoiding hypoglycaemia; do not use routine intensive intravenous insulin. Test HbA1c and fasting glucose before discharge if no diabetes, and tell the patient and their general practitioner that annual screening is needed thereafter. ^[3]

Colchicine. The ESC suggests considering low-dose colchicine, 0.5 mg once daily, when cardiovascular events recur or risk factors remain uncontrolled despite optimal therapy. ^[2] This is a more recent ESC position than most NICE guidance, and the evidence for hard-outcome benefit in all post-ACS patients continues to accumulate.

Implantable cardioverter defibrillator (ICD). In patients with a pre-discharge LVEF below 40%, the need for an ICD (or cardiac resynchronisation therapy with a defibrillator) should be assessed 6 to 12 weeks after the ACS, after successful revascularisation and initiation of optimal medical therapy: repeat the LVEF and consider cardiac magnetic resonance imaging. ^[2] NICE offers this option for severe LV dysfunction (LVEF at most 35%). ^[3] Do not promise an ICD on discharge; most hearts recover enough that the trigger is not met.

• Lipids. After the first ACS, the goal is LDL-C below 1.4 mmol/L (below 55 mg/dL) and a reduction of at least 50% from baseline. Recheck lipids 4 to 6 weeks after the event; if the maximum tolerated high-intensity statin does not reach the goal, add ezetimibe, and a PCSK9 inhibitor if the goal is still missed. If triglycerides remain elevated at 1.5 to 1.6 mmol/L, icosapent ethyl 2 g twice daily with a statin may be started. For a recurrence within 2 years, aim for LDL-C below 1.0 mmol/L. ^[1]
• Blood pressure. Treat hypertension per standard guidance; ACE inhibitors are indicated when any of LVEF at most 40%, heart failure, diabetes, hypertension, or chronic kidney disease are present (and should be considered for all ACS patients). ^[2]
• Influenza vaccination. Recommended for all ACS patients. ^[2]
• Smoking and alcohol. Tobacco abstinence cuts reinfarction by 30 to 40% and death by 35 to 45% after an ACS, so cessation is the single highest-yield behaviour change. Alcohol should be limited to no more than 100 mL per week. ^[6]
• Diet and weight. A Mediterranean style diet. ^[3]
• Activity. Build to at least 20 to 30 minutes a day of moderate exertion (slight breathlessness) for people not already active; add muscle-strengthening work twice weekly. Daily physical activity does not replace exercise-based rehabilitation. ^[3][6]
• Mental wellbeing. Assess with a validated tool before discharge and refer onwards when needed. ^[2][6]
• Monitoring after discharge. Reassess LV function 8 to 12 weeks after revascularisation if it was impaired, because contractility can recover from stunning or hibernation. At least two outpatient visits in the first year are usual, with individual risk reassessment. ^[6]

• Bleeding risk should be assessed at follow-up. ^[3]
• Patients on anticoagulation for atrial fibrillation should receive triple therapy for no more than one week after ACS, then anticoagulation with a single antiplatelet for 12 months, then anticoagulation alone. ^[1]
• Prolonging antiplatelet therapy beyond 12 months (ticagrelor 60 mg twice daily or rivaroxaban 2.5 mg twice daily added to aspirin) is for high-ischaemic-risk patients without high bleeding risk. ^[1]
• A polypill containing secondary-prevention drugs can be considered to improve adherence; in the SECURE trial it was associated with a 33% reduction in cardiovascular mortality. ^[1]
• Report any recurrent chest pain, dyspnoea, syncope or new palpitations promptly.

Where ESC and NICE differ, be honest with the patient: ESC recommends beta-blockers for all ACS patients (even preserved EF) and supports longer or more intense antiplatelet regimens, while NICE limits indefinite beta-blockers to reduced EF and does not recommend routine long-term dual antiplatelet therapy beyond 12 months except in high-risk patients. Both agree on aspirin, ACE inhibitors (with reduced EF or other indications), statins, rehabilitation and risk-factor control. The safest practice is to treat to the more protective option that the patient can tolerate, and to document why. ^[1][2][3]

Cardiac rehabilitation is a coordinated and structured programme, not a gym membership. Its standard content is exercise, health education, lifestyle advice and stress management, and it is the most effective vehicle for secondary prevention. ^[3]

• Who. Every person after an MI, regardless of age, is advised about and offered a programme with an exercise component. People with reduced LVEF who are stable can safely have exercise. ^[3]
• When. Start in hospital, before discharge, and arrange an assessment appointment within 10 days of discharge. ^[3] All ACS patients should participate in a comprehensive programme that starts as early as possible after the event. ^[6]
• Where and how. Offer a choice of venues (hospital, community or home-based, such as a validated home programme) and times (including outside working hours), because transport, work and language are the real barriers to attendance. Do not exclude people from the whole programme if they decline one component. ^[3]
• Safety. Treat exercise-worsening conditions first, and have the exercise component adapted by a suitably qualified professional when needed. ^[3]
• Accessibility. Programmes should be non-judgemental and culturally sensitive, equally accessible to women, older people, ethnic minorities, rural and lower-socio-economic groups, and people with disabilities. ^[3]
• Promotion. Every member of the team, including senior medical staff, should actively promote attendance; studies still show low referral and participation rates despite proven benefit. ^[3][6]
• Psychological and social care. Comprehensive programmes include health education and stress management; cognitive behavioural therapy is not routinely offered; partners may be involved. Manage proven depression or anxiety via standard mental-health pathways. ^[3]

Exercise intensity is best individualised. A practical proxy from NICE: 20 to 30 minutes of daily physical activity at a level producing slight breathlessness, increasing gradually with perceived exertion scales. The MET (metabolic equivalent) tables used to compare the demands of activities can be found in CDC references; use them for advice on return to heavy work or sport. ^[3]

These rules vary by country; the UK DVLA figures below are given as one concrete, current example. NICE advises clinicians to be up to date with DVLA guidance. ^[3]

Car or motorcycle licence (ordinary vehicles):

• you do not need to tell the DVLA after an MI or angioplasty;
• stop driving for 1 week after a successful angioplasty with no further surgery planned; ^[4]
• stop for 4 weeks after an unsuccessful angioplasty, or after an MI not treated by angioplasty. ^[4]

Group-2 (bus, coach, lorry) driving is stricter: 6 weeks off work and you must tell the DVLA, followed by a medical assessment against the fitness standards, with specific tests where the condition requires them. ^[4]

• Air travel: after an uncomplicated MI, seek advice from the Civil Aviation Authority; complicated MIs need individual expert advice. ^[3]
• Pilot's licence holders must consult the Civil Aviation Authority. ^[3]
• Competitive sport needs individual expert assessment of function and risk. ^[3]
• Heavy manual or hazardous work should be guided by MET tables and how the patient feels under exertion. ^[3]

There is no universal "six weeks" rule. Advice should account for the person's physical and psychological status, the nature of their work and work environment. ^[3] Desk-based or light work often resumes within a few weeks; heavy, safety-critical or emotionally demanding work (professional driving, construction, firefighting) needs individual assessment and sometimes functional testing. Many patients feel unexpectedly tired for several weeks; tiredness itself is an important red flag if it suggests ischaemia or depression rather than deconditioning.

After an uncomplicated MI, sexual activity presents no greater risk of triggering another infarct than before, and it can usually be resumed about 4 weeks after recovery, when the patient feels comfortable. ^[3] Raise the subject in rehabilitation, because most patients will ask only if invited.

• Heart failure after an MI. Manage as chronic heart failure; beta-blockers and ACE inhibitors are indefinite and mineralocorticoid receptor antagonists (aldosterone antagonists) are added for symptomatic heart failure with reduced EF. ^[3]
• Device therapy. ICD and cardiac resynchronisation are considered for LV dysfunction, especially LVEF at most 35%. ^[3]
• Pregnancy and the postpartum period need a cardiologist-obstetric team; the standard drug set has pregnancy considerations that are beyond this page's scope.
• Older and frail adults. Polypharmacy and impaired renal function limit uptitration; a polypill may help adherence. ^[1]
• Low-resource settings. Echocardiography is the key investigation and may be the only test that changes decisions. Where antiplatelets, statins and ACE inhibitors are available, start them and uptitrate as renal function allows; where complex laboratory follow-up is not, use clinical targets (blood pressure, symptoms, weight) and accessible exercise-based rehabilitation, which can be home-based. ^[3][6]

• Same-day specialist review: suspected mechanical complication, recurrent chest pain, syncope, sustained palpitations, or a pericardial effusion greater than 10 mm. ^[2][5]
• Cardiology outpatients promptly: anyone with LVEF below 40%, a new significant arrhythmia, severe hypertension, or intolerance to key drugs.
• Early echocardiography after discharge whenever symptoms suggest recurrent ischaemia, a falling LVEF, or a new murmur.
• Psychological support for marked anxiety or depression, which is common and which worsens adherence. ^[3]

• The first weeks after an MI are when mechanical, arrhythmic and pericardial complications appear; early reperfusion has made them less common, but they remain life-threatening and surgical.
• Mechanical complications (free-wall rupture, ventricular septal rupture, papillary-muscle rupture) are emergencies and need surgical or catheter-based repair. ^[2]
• Arrhythmias are managed first by treating ischaemia and correcting electrolytes, with sustained monitoring in high-risk patients. ^[2]
• Pericarditis after an MI is now rare (both early and late forms under 5% and under 1% respectively); early pericarditis is self-limited and treated with aspirin (steroids are avoided), while Dressler syndrome appears weeks later. ^[5]
• Secondary prevention rests on aspirin, a P2Y12 inhibitor for up to 12 months, an ACE inhibitor, a beta-blocker, a high-intensity statin, and (for some) a mineralocorticoid receptor antagonist and low-dose colchicine. ^[2][3]
• Lipid target after first MI: LDL-C below 1.4 mmol/L with at least a 50% reduction, rechecked at 4 to 6 weeks, escalating through ezetimibe to a PCSK9 inhibitor. ^[1]
• Aspirin continues indefinitely; beta-blockers are indefinite with reduced EF, and considered for 12 months with preserved EF. ^[3]
• Angiotensin-converting enzyme (ACE) inhibitors continue indefinitely after an MI and are titrated to the maximum tolerated dose within 4 to 6 weeks of discharge, with renal and electrolyte monitoring. ^[3]
• Aldosterone antagonists are added 3 to 14 days after infarction when there is heart failure with reduced EF. ^[3]
• Blood glucose is kept below 11.0 mmol/L acutely, with HbA1c and fasting-glucose testing and annual screening before discharge. ^[3]
• Cardiac rehabilitation is for everyone after an MI, regardless of age, and should start in hospital with an assessment within 10 days of discharge. ^[3][6]
• Rehabilitation must include exercise, health education, lifestyle advice and stress management; access and cultural sensitivity matter as much as the exercise programme. ^[3]
• Smoking, a Mediterranean diet, weight and regular activity are part of the prescription; smoking cessation alone cuts reinfarction by 30 to 40% and death by 35 to 45%. ^[3][6]
• Alcohol limit: no more than 100 mL per week. ^[6]
• Mental wellbeing should be assessed before discharge and patients referred when indicated; depression and anxiety worsen adherence. ^[2][6]
• Driving pauses for 4 weeks after uncomplicated MI without angioplasty (UK DVLA example); return to work is individual and takes the job and heart function into account. ^[4]
• Sexual activity is safe about 4 weeks after an uncomplicated recovery and should be discussed openly. ^[3]
• Patients with a pre-discharge LVEF below 40% are assessed for an ICD at 6 to 12 weeks, and LV function is reassessed at 8 to 12 weeks after revascularisation. ^[2][6]
• Follow-up lipid targets, blood pressure, symptoms, exercise capacity and mental wellbeing, and escalate when a target is missed.

• Myocardial infarction (acute presentation and reperfusion)
• Acute coronary syndromes
• Heart failure
• Atrial fibrillation
• Cardiogenic shock
• Pericarditis
• Dyslipidaemia and lipid lowering
• Cardiac physical examination
• ECG interpretation
• Echocardiography
• Secondary prevention of cardiovascular disease